trending Market Intelligence /marketintelligence/en/news-insights/trending/gxlddihnv1tnsdatxhtkcg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Lixte Biotechnology names 2 directors

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


Lixte Biotechnology names 2 directors

Lixte Biotechnology Holdings Inc. appointed Yun Yen and Winson Ho to its board.

Yen is president emeritus of Taipei Medical University and chair professor of the doctorate program for cancer biology and drug discovery.

Ho is a pediatric neurosurgery fellow at the University of Utah School of Medicine. He previously served as a research fellow at a division of the National Institutes of Health, and conducted research on Lixte's lead clinical compound.

New York-based Lixte Biotechnology develops treatments for cancer and nonmalignant diseases.